At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 233 enrolled
Drug / intervention
Hexvix +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Comparative Phase III, 2-center Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer
In Brief
A Phase 3 clinical trial evaluating Hexvix and Standard white light cystoscopy for Bladder Cancer. Completed, enrolled 233 participants across 2 sites.
Detailed Summary
The main objective of the study is to compare the 1-year recurrence rate of Hexvix assisted Transuretheral Resection of the Bladder (TURB) to standard white light TURB in patients with suspicion of non-invasive bladder cancer. The hypothesis is to test whether the 1-year recurrence rate is different with Hexvix assisted TURB compared to standard white light TURB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesDenmark
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedDec 2006
Primary CompletionOct 2008
TodayJul 2026
First PostedDec 19, 2006
Enrollment StartApr 1, 2005
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 19.5 years ago
Interventions
Hexvixdrug
Single installation, TURB
Standard white light cystoscopyother